$CRSP
CRISPR Therapeutics AG Stock $crsp

$crsp Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021006074 Filed on February 16, 2021

Income Statement

Concept	2020 Q4	2020 Q2	2020 Q1
Revenue	$370.0K	$44.00K	$157.0K
YoY Change	-99.52%	-86.16%	-52.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$25.80M	$21.40M	$19.60M
YoY Change	49.13%	35.44%	31.54%
% of Gross Profit
Research & Development	$82.40M	$59.38M	$54.19M
YoY Change	68.85%	50.2%	60.23%
% of Gross Profit
Depreciation & Amortization	$2.560M	$2.200M	$2.091M
YoY Change	77.78%	120.0%	157.51%
% of Gross Profit
Operating Expenses	$108.1M	$80.73M	$73.74M
YoY Change	63.75%	45.99%	51.26%
Operating Profit	-$107.8M	-$80.69M	-$73.59M
YoY Change	-1081.16%	46.75%	51.96%
Interest Expense	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$600.0K	$1.412M	$4.232M
YoY Change	-96.94%	3.14%	4132.0%
Pretax Income	-$107.2M	-$79.28M	-$69.35M
YoY Change	-451.48%	47.87%	43.52%
Income Tax	-$100.0K	$400.0K	$400.0K
% Of Pretax Income
Net Earnings	-$107.0M	-$79.66M	-$69.73M
YoY Change	-450.46%	48.34%	44.05%
Net Earnings / Revenue	-28929.46%	-181036.36%	-44414.65%
Basic Earnings Per Share	-$1.50	-$1.30	-$1.15
Diluted Earnings Per Share	-$1.50	-$1.30	-$1.15
COMMON SHARES
Basic Shares Outstanding	71.28M	61.42M	60.85M
Diluted Shares Outstanding	71.28M	61.42M	60.85M

Balance Sheet

Concept	2020 Q4	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.169B	$945.1M	$889.7M
YoY Change	23.86%	120.87%	103.36%
Cash & Equivalents	$1.169B	$945.1M	$889.7M
Short-Term Investments	$395.1K
Other Short-Term Assets	$26.10M	$20.50M	$14.50M
YoY Change	-40.27%	99.03%	21.85%
Inventory
Prepaid Expenses
Receivables	$144.0K	$0.00	$25.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.717B	$965.6M	$929.3M
YoY Change	73.83%	120.22%	106.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.16M	$34.44M	$31.77M
YoY Change	34.57%	70.89%	68.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.293M	$7.000M	$662.0K
YoY Change	17.87%	946.34%	-82.58%
Total Long-Term Assets	$111.3M	$80.90M	$78.00M
YoY Change	40.58%	45.05%	62.15%
TOTAL ASSETS
Total Short-Term Assets	$1.717B	$965.6M	$929.3M
Total Long-Term Assets	$111.3M	$80.90M	$78.00M
Total Assets	$1.828B	$1.047B	$1.007B
YoY Change	71.36%	111.74%	102.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.094M	$13.20M	$11.28M
YoY Change	52.99%	84.8%	58.83%
Accrued Expenses	$53.78M	$36.69M	$21.92M
YoY Change	78.2%	96.93%	6.43%
Deferred Revenue	$2.341M		$803.0K
YoY Change	143.85%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$94.26M	$74.50M	$55.09M
YoY Change	65.06%	137.17%	93.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.630M	$61.40M	$11.95M
YoY Change	-47.0%	27809.09%	-86.68%
Total Long-Term Liabilities	$7.630M	$61.40M	$11.95M
YoY Change	-47.0%	27809.09%	-86.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.26M	$74.50M	$55.09M
Total Long-Term Liabilities	$7.630M	$61.40M	$11.95M
Total Liabilities	$163.7M	$135.9M	$121.2M
YoY Change	28.59%	7.38%	2.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$573.6M		-$294.4M
YoY Change	155.25%
Common Stock	$2.238B		$1.181B
YoY Change	92.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$63.00K		$63.00K
YoY Change	0.0%
Treasury Stock Shares	$195.3K		$232.4K
Shareholders Equity	$1.664B	$910.7M	$886.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.828B	$1.047B	$1.007B
YoY Change	71.36%	111.74%	102.32%

Cashflow Statement

Concept	2020 Q4	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$107.0M	-$79.66M	-$69.73M
YoY Change	-450.46%	48.34%	44.05%
Depreciation, Depletion And Amortization	$2.560M	$2.200M	$2.091M
YoY Change	77.78%	120.0%	157.51%
Cash From Operating Activities	-$81.22M	-$29.27M	-$52.18M
YoY Change	-2502.96%	-19.54%	19.29%
INVESTING ACTIVITIES
Capital Expenditures	-$6.240M	-$3.610M	$2.991M
YoY Change	556.84%	66.36%	172.65%
Acquisitions
YoY Change
Other Investing Activities	-$198.0M
YoY Change	-2571.91%
Cash From Investing Activities	-$204.2M	-$3.610M	-$2.991M
YoY Change	-2992.92%	66.36%	172.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	412.6M	89.51M	1.132M
YoY Change	35.41%	201.89%	-95.6%
NET CHANGE
Cash From Operating Activities	-81.22M	-29.27M	-52.18M
Cash From Investing Activities	-204.2M	-3.610M	-2.991M
Cash From Financing Activities	412.6M	89.51M	1.132M
Net Change In Cash	127.2M	56.63M	-54.06M
YoY Change	-59.65%	-736.29%	183.03%
FREE CASH FLOW
Cash From Operating Activities	-$81.22M	-$29.27M	-$52.18M
Capital Expenditures	-$6.240M	-$3.610M	$2.991M
Free Cash Flow	-$74.98M	-$25.66M	-$55.17M
YoY Change	-1831.64%	-24.99%	23.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113773000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	719000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	289590000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3124000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	266946000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	179362000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63488000
CY2018	us-gaap	Operating Expenses OperatingExpenses	162067000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60953000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164428000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	553000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20566000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25747000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5025000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8563000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	939425000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	973381000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	7000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2538000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	32618000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3342000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6379000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-348056000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	67306000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	809000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	448000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	66873000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165003000
CY2018	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201409Member
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943771000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	521713000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	144000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	99000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26143000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43677000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1716620000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	987547000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42160000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31330000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	180000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	235000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16848000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5041000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50865000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41502000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3519000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	44057000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50067000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44050000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7630000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14395000
CY2020Q4	us-gaap	Liabilities Liabilities	163732000
CY2019Q4	us-gaap	Liabilities Liabilities	127327000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2277000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1847000
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	195316
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	250226
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	63000
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	63000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2235679000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1162345000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-573576000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115172786
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103901006
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74110160
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61034025
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73914844
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60783799
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1293000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1097000
CY2020Q4	us-gaap	Assets Assets	1827966000
CY2019Q4	us-gaap	Assets Assets	1066752000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9094000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5944000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53782000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30180000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2341000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	960000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	10473000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	583000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11362000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8489000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7207000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10950000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94259000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57106000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11776000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11776000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224711000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-83000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1664234000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	939425000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1827966000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1066752000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88208000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48294000
CY2020	us-gaap	Operating Expenses OperatingExpenses	355154000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5467000
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4275000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6379000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26033000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1210000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5485000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-541170000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1325000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	982289000
CY2019	crsp	Research And Development Expense From Related Party ResearchAndDevelopmentExpenseFromRelatedParty	14459000
CY2018	crsp	Research And Development Expense From Related Party ResearchAndDevelopmentExpenseFromRelatedParty	23982000
CY2019	us-gaap	Operating Expenses OperatingExpenses	242850000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-354435000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	46740000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-158943000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-130000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-348955000
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.29
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65949672
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54392304
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47964368
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.29
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.17
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65949672
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56932798
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47964368
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	746000
CY2018	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3124000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	187832000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	307053000
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	113000
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	57000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39260000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	392195000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414789000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	43000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16001000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49524000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	15000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32775000
CY2020	crsp	Stock Purchased During Period Value Employee Stock Purchase Plan StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan	694000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66018000
CY2020	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	889000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-90000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-348865000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1664234000
CY2020	us-gaap	Profit Loss ProfitLoss	-348865000
CY2019	us-gaap	Profit Loss ProfitLoss	66858000
CY2018	us-gaap	Profit Loss ProfitLoss	-164981000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9184000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4725000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	66018000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	34985000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5467000
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4275000
CY2018	crsp	Non Cash Expense Related To Collaboration Agreement NonCashExpenseRelatedToCollaborationAgreement	15582000
CY2019	crsp	Gain Loss From Consolidation Of Subsidiary GainLossFromConsolidationOfSubsidiary	16000000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1857000
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	169000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	45000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16800000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5041000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3163000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1185468000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	948812000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17338000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12110000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1381000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-45146000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-296000
CY2018	crsp	Increase Decrease In Deferred Rent Payable IncreaseDecreaseInDeferredRentPayable	-709000
CY2020	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	-473000
CY2019	crsp	Increase Decrease In Operating Lease Assets And Liabilities IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities	-663000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10508000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	24983000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	249000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-238366000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56677000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96239000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18358000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6684000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2773000
CY2019	crsp	Net Cash And Restricted Cash Received In Connection With Acquisition Of Controlling Interest NetCashAndRestrictedCashReceivedInConnectionWithAcquisitionOfControllingInterest	8009000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	593998000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	71186000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2773000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	415019000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	307053000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	33863000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	15964000
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8938000
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	57000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1016152000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	430983000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	315934000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-22000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	236656000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	489000000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	216900000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	948812000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	242912000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3412000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1811000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	334000
CY2020	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	9590000
CY2019	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	295000
CY2018	crsp	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	375000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1168620000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943771000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	456649000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16848000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31330000
CY2020	us-gaap	Depreciation Depreciation	9100000
CY2019	us-gaap	Depreciation Depreciation	4700000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5000000.0
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1185468000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	948812000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	459812000
CY2020	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-10-31
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-573600000
CY2020Q4	crsp	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	1690300000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66900000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-348900000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1168600000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	943800000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	521700000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0.0
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-balance Sheet Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss. </p>
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	300000
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	25700000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12200000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12700000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	1900000
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	0
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1202000
CY2018	us-gaap	Sublease Income SubleaseIncome	176000
CY2020Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2019Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	395100000
CY2020Q4	crsp	Cash Equivalents Gross Unrealized Gains Before Tax CashEquivalentsGrossUnrealizedGainsBeforeTax	1000
CY2020Q4	crsp	Cash Equivalents Gross Unrealized Losses Before Tax CashEquivalentsGrossUnrealizedLossesBeforeTax	24000
CY2020Q4	crsp	Cash Equivalents Fair Value CashEquivalentsFairValue	773537000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	521820000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	51000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	158000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	521713000
CY2020Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	1295380000
CY2020Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax	52000
CY2020Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax	182000
CY2020Q4	crsp	Cash Equivalents And Available For Sale Debt Securities Fair Value CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue	1295250000
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	280300000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	100000
CY2020Q4	crsp	Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear	0
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63335000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43376000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21175000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12046000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42160000
CY2018	us-gaap	Depreciation Depreciation	3500000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22402000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15229000
CY2020Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	21684000
CY2019Q4	crsp	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9434000
CY2020Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	1401000
CY2019Q4	crsp	Accrued License Fees Current AccruedLicenseFeesCurrent	750000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1670000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2040000
CY2020Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	3625000
CY2019Q4	crsp	Accrued Intellectual Property Costs Current AccruedIntellectualPropertyCostsCurrent	2311000
CY2020Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	2835000
CY2019Q4	crsp	Accrued Property And Equipment AccruedPropertyAndEquipment	407000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	165000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53782000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30180000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50865000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41502000
CY2020Q4	crsp	Lease Assets LeaseAssets	50865000
CY2019Q4	crsp	Lease Assets LeaseAssets	41502000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11362000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8489000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50067000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44050000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	61429000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52539000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	14342000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	8067000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7339000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4554000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	6368000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	4282000
CY2020	us-gaap	Sublease Income SubleaseIncome	587000
CY2019	us-gaap	Sublease Income SubleaseIncome	525000
CY2020	us-gaap	Lease Cost LeaseCost	27462000
CY2019	us-gaap	Lease Cost LeaseCost	16378000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17020000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13815000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12650000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10761000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10265000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	37206000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	101717000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	40288000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	61429000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.099
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	13161000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8420000
CY2020	crsp	Right Of Use Assets Increased Through Lease Modifications And Reassessments RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments	3169000
CY2019	crsp	Right Of Use Assets Increased Through Lease Modifications And Reassessments RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments	826000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13956000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18088000
CY2020	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	4500000
CY2019	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	2900000
CY2018	crsp	Cost Sharing Expenses Incurred CostSharingExpensesIncurred	2400000
CY2020	crsp	Cost Sharing Expenses Accrued CostSharingExpensesAccrued	2500000
CY2019	crsp	Cost Sharing Expenses Accrued CostSharingExpensesAccrued	1500000
CY2020	crsp	Joint Venture Agreement Date JointVentureAgreementDate	2015-12-19
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6784000
CY2020Q4	crsp	Prepaid Expenses And Other Current Assets Fair Value Disclosure PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure	2565000
CY2020Q4	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	9340000
CY2020Q4	crsp	Operating Lease Assets Fair Value Disclosure OperatingLeaseAssetsFairValueDisclosure	11003000
CY2020Q4	crsp	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	1226000
CY2020Q4	crsp	Accrued Expenses And Other Current Liabilities Fair Value Disclosure AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure	3915000
CY2020Q4	crsp	Operating Lease Liabilities Fair Value Disclosure OperatingLeaseLiabilitiesFairValueDisclosure	11003000
CY2020Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	16000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115172786
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103901006
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.03
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2209597
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	68.91
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.16
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	51.73
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.28
CY2020Q4	crsp	Common Stock Registered Share Capital CommonStockRegisteredShareCapital	75133951
CY2019Q4	crsp	Common Stock Registered Share Capital CommonStockRegisteredShareCapital	61036566
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115172786
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	103901006
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2906383
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote for each Common Share
CY2020	us-gaap	Dividends Dividends	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66000000.0
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49500000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39300000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66018000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49524000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39260000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	132500000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2182773
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2832784
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.57
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.82
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.692
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.689
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.719
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65949672
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54392304
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47964368
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65949672
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56932798
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47964368
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.29
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.29
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.17
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7782437
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	231554000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2182773
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	68.91
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1517735
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	23.53
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	345495
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	41.61
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8101980
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.44
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	896666000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3838372
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.43
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	470907000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8101980
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	42.44
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	896666000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	104200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	42200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38300000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-348865000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	66858000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-164981000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	67306000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-164428000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	248000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	131000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	9155000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5966000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-355686000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	58151000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-170394000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-348056000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	400000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	482000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	547000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9007329
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3897754
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7016653
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1900000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7630000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	423000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	416000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	151000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	59000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	136832000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9605000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5217000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	86000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116640000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45913000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	409000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-34000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	409000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-34000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	809000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	448000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	553000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.093
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.093
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.021
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004
CY2020	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.000
CY2019	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.001
CY2018	crsp	Effective Income Tax Rate Reconciliation Statutory Permanent Differences EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences	0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.023
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.014
CY2020	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0.000
CY2019	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	-0.122
CY2018	crsp	Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.033
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.052
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.187
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.109
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.141
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	84531000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31496000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4785000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2868000
CY2020Q4	crsp	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	16782000
CY2019Q4	crsp	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	14214000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1517000
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	20000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19526000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7150000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15040000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	20192000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6778000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3901000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	80733000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	92547000
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	108131000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-73586000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-80689000
CY2020Q4	crsp	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	13776000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-92399000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-107761000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-69731000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-79656000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-92439000
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	73743000
CY2019Q4	crsp	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	11068000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	31000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	40000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	20000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20589000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15029000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	397000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	70700000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1416700000
CY2020	crsp	Operating Loss Carryforwards Expiration Period OperatingLossCarryforwardsExpirationPeriod	2023
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12000000.0
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	11000000.0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2019Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2018Q4	crsp	Uncertain Tax Position Recognized UncertainTaxPositionRecognized	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5231000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	354000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7004000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2754000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1212000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	882000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	29000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	268000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11967000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5231000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	157000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	370000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-107039000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60847683
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61420746
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70143481
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.50
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60847683
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61420746
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70143481
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71282096
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71282096
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	328000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211928000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77016000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	48751000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	55301000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	72765000
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	66033000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48423000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-54983000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	139163000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	10983000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-48408000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-53699000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	138423000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	30542000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.52
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.53
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.40
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52093208
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53188041
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54829057
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57395839
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52093208
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53188041
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57598901
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60233927

Files In Submission

Name	View Source	Status
0001564590-21-006074-index-headers.html	Edgar Link	pending
0001564590-21-006074-index.html	Edgar Link	pending
0001564590-21-006074.txt	Edgar Link	pending
0001564590-21-006074-xbrl.zip	Edgar Link	pending
crsp-10k_20201231.htm	Edgar Link	pending
crsp-10k_20201231_htm.xml	Edgar Link	completed
crsp-20201231.xsd	Edgar Link	pending
crsp-20201231_cal.xml	Edgar Link	unprocessable
crsp-20201231_def.xml	Edgar Link	unprocessable
crsp-20201231_lab.xml	Edgar Link	unprocessable
crsp-20201231_pre.xml	Edgar Link	unprocessable
crsp-ex211_16.htm	Edgar Link	pending
crsp-ex231_15.htm	Edgar Link	pending
crsp-ex311_18.htm	Edgar Link	pending
crsp-ex312_11.htm	Edgar Link	pending
crsp-ex31_9.htm	Edgar Link	pending
crsp-ex321_13.htm	Edgar Link	pending
crsp-ex41_17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gvbp5gh2dv4g000001.jpg	Edgar Link	pending
gvbp5gh2dv4g000002.jpg	Edgar Link	pending
gvbp5gh2dv4g000003.jpg	Edgar Link	pending
gvbp5gh2dv4g000004.jpg	Edgar Link	pending
gvbp5gh2dv4g000005.jpg	Edgar Link	pending
gvbp5gh2dv4g000006.jpg	Edgar Link	pending
gvbp5gh2dv4g000007.jpg	Edgar Link	pending
gvbp5gh2dv4g000008.jpg	Edgar Link	pending
gvbp5gh2dv4g000009.jpg	Edgar Link	pending
gvbp5gh2dv4g000010.jpg	Edgar Link	pending
gvbp5gh2dv4g000011.jpg	Edgar Link	pending
gvbp5gh2dv4g000012.jpg	Edgar Link	pending
gvbp5gh2dv4g000013.jpg	Edgar Link	pending
gvbp5gh2dv4g000014.jpg	Edgar Link	pending
gvbp5gh2dv4g000015.jpg	Edgar Link	pending
gvbp5gh2dv4g000016.jpg	Edgar Link	pending
gvbp5gh2dv4g000017.jpg	Edgar Link	pending
gvbp5gh2dv4g000018.jpg	Edgar Link	pending
gvbp5gh2dv4g000019.jpg	Edgar Link	pending
gvbp5gh2dv4g000020.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRSP
CRISPR Therapeutics AG Stock $crsp

2020 Q4 Form 10-K Financial Statement

#000156459021006074 Filed on February 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP CRISPR Therapeutics AG Stock $crsp

2020 Q4 Form 10-K Financial Statement

#000156459021006074 Filed on February 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRSP
CRISPR Therapeutics AG Stock $crsp